Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)

Summary

The study aims to evaluate the efficacy of a third TKI after two previous lines of therapy with TKIs, in terms of median progression free survival (mPFS), in patients affected by metastatic renal cancer cell. Patients receiving the sequence Sunitinib- Axitinib, will receive Sorafenib. Patients receiving the sequence Pazopanib-Sorafenib, will receive Sunitinib. Sorafenib dosage 400mg orally, twice a day. Sunitinib dosage 50 mg 4 weeks on followed by 2 weeks a rest. The therapy will be continued until disease progression or unacceptable toxicity.

Timeline

Start

2014-11

Primary completion

2017-11-08

Completion

2017-11-08

Outcome

Outcome not reported

Stopped: “availability of new and more promising therapeutic agents than expected in the experimentation in question”

Drugs

Indications